We would like to use cookies to optimize and continuously improve our website for you.
Please agree to the use of cookies for our website.
You can find further information in our data protection declaration.

Reliable Alzheimer’s early detection and risk diagnostics with Predemtec DX

Background

Alzheimer’s is the most common form of dementia and is currently untreatable. It is a degenerative disease of the brain that mostly affects people advanced in age. The disease is still to this day diagnosed too late. This delayed diagnosis translates to fewer therapeutic options.

There is strong evidence that Alzheimer’s begins 10 to 15 years before the onset of initial clinical symptoms. Pathological processes are compensated for by central nervous system mechanisms which allow the disease to remain undetected for an extended period of time. During this clinically undetectable phase, biological changes identifiable by biomarkers occur.

Predemtec DX

Predemtec DX can be implemented if the initial indications of Alzheimer’s are presumed. This often pertains to people with cognitive deficiencies and symptoms of memory loss as well as those advanced in age (50 plus) with underlying conditions e. g. diabetes and high blood pressure.

When diagnosed early, disease-modifying treatment approaches for biomarker specific therapies can be initiated. Likewise, there is a need for early diagnostics for medications that have so far been approved for delaying the disease’s advancement and proven effective in the development of therapeutic agents. Irrespective of various treatments, a change in lifestyle can also delay the onset of the disease in those at increased risk of Alzheimer’s by years.

Zum Seitenanfang